Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ninian N Lang

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
European Journal of Heart Failure|September 12, 2025
Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-OncologyKalliopi Keramida, Teresa Lopez-Fernandez, Markus S Anker, et al.
Cardiovascular Research|July 24, 2020
The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) studyKenneth Mangion, Andrew Morrow, Catherine Bagot, et al.
European Journal of Heart Failure|May 14, 2024
Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HFJames P Curtain, Atefeh Talebi, Alasdair McIntosh, et al.
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Lancet (London, England)|November 8, 2022
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R Kalra, John G F Cleland, Mark C Petrie, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Circulation|September 25, 2023
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE TrialPeter A Henriksen, Peter Hall, Iain R MacPherson, et al.
JAMA Network Open|December 3, 2025
Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical TrialCongying Xia, Amanda M Smith, Bénédicte Lefebvre, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
European Journal of Heart Failure|September 12, 2025
Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-OncologyKalliopi Keramida, Teresa Lopez-Fernandez, Markus S Anker, et al.
Cardiovascular Research|July 24, 2020
The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) studyKenneth Mangion, Andrew Morrow, Catherine Bagot, et al.
European Journal of Heart Failure|May 14, 2024
Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HFJames P Curtain, Atefeh Talebi, Alasdair McIntosh, et al.
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
European Journal of Heart Failure|February 23, 2021
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trialNinian N Lang, Faheem A Ahmad, John G Cleland, et al.
Lancet (London, England)|November 8, 2022
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R Kalra, John G F Cleland, Mark C Petrie, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Circulation|September 25, 2023
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE TrialPeter A Henriksen, Peter Hall, Iain R MacPherson, et al.
JAMA Network Open|December 3, 2025
Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical TrialCongying Xia, Amanda M Smith, Bénédicte Lefebvre, et al.
Pageof 9